AbbVie trial data case in EU delayed; Hospira, Sandoz settle Precedex fight; PhRMA fights 2nd drug takeback law;

@FiercePharma: GSK fends off wrongful death case alleging Paxil led to abortion. News | Follow @FiercePharma

@EricPFierce: Mylan intends to launch 800 injectable products in next 5 years--150 in U.S.--now that it owns Agila. Story | Follow @EricPFierce

@CarlyHFierce: SEC: Provenge critic lied about her bets Dendreon stock would fall. Yesterday's story | Follow @CarlyHFierce

> PhRMA is fighting another drug disposal law, this one in Washington. Story

> A case by AbbVie ($ABBV) and InterMune ($ITMN) to prevent EU regulators from publicly releasing trial data has been returned to a lower court for review. Story

> Hospira ($HSP) has settled a patent case with Novartis' ($NVS) Sandoz Canada unit allowing it to bring a generic of Hospira's sedation drug Precedex to market by Dec. 26, 2014. Report

> The Financial Times says AstraZeneca ($AZN) may be interested in buying Forest Laboratories ($FRX). Story (sub. req.)

> Japan's Daiichi Sankyo Healthcare has halted sales of its skin lotions, distributed by mail order, after receiving 270 complaints about swollen or itchy skin. Report

> A new report says that with few treatment options available, many governments are not prepared to deal with an epidemic of dementia that is expected to affect 135 million people by 2050. Story

Medical Device News

@FierceMedDev: That didn't take long: Myriad Genetics targets LabCorp with BRCA patent suit. Item | Follow @FierceMedDev

@MarkHFierce: DioGenix pulled in $3.2M in private financing to fuel continued work on its MS diagnostic test. Release | Follow @MarkHFierce

@MichaelGFierce: BioDelivery Sciences is moving ahead on its #diabetes pain gel with the FDA's blessing. Story | Follow @MichaelGFierce

@GalenMoore: BofA: neratinib likely to do well in trials as an adjuvant & 3rd line for metastatic breast cancer. Note via @bradloncar | Follow @GalenMoore

> Medtronic's new version of Symplicity gets a green light in EU and Australia. News

> Cardiac stents fall short versus surgery, drugs in 2 new JAMA studies. More

Biotech News

@FierceBiotech: I-SPY a controversy over Puma's positive PhII test of neratini. Story | Follow @FierceBiotech

@JohnCFierce: My favorite dysfunctional pharma company, Eli Lilly, reports yet another PhIII flop. Release | Follow @JohnCFierce

@DamianFierce: If Transcept can't find a buyer, it's going to liquidate come Q2. Release | Follow @DamianFierce

@EmilyMFierce: Cellular Dynamics and Jain Foundation partner on stem cell models for muscular dystrophy. News | Follow @EmilyMFierce

> Lilly extends its streak of PhIII failures, scraps another program. More

> PaxVax snags $22M to get fast-tracked cholera pill through Phase III. Story

> FDA questions safety of Takeda's blockbuster-hopeful bowel disease drug. Article

Vaccines News

> The argument for vaccinating: 100M cases of disease prevented in U.S. Story

> Nonprofit crowdfunding tech-enabled HIV vaccine project. Piece

> Whooping cough vaccine fails to stop spread of disease in FDA animal study. More

> TB vaccine shows promise in preventing MS. News

> CDC considers expanding use of Bexsero as meningitis outbreak spreads. Article

> PaxVax raises $22M for PhIII trial of cholera vaccine. Item

Pharma Manufacturing News

> In cancer immunotherapy joint venture, Fred Hutch and MSKCC face manufacturing challenges. Piece

> Pfizer whacking 150 jobs in closure of Irish packaging plant. News

> FDA warning letter tasks Wockhardt with global plant assessment. More

> PhRMA begins another lawsuit against a drug-disposal law. Story

> Boehringer taps BofA to talk up potential of sterile injectables plant. Article

> Patheon invests in U.K. plant, posts operating loss. Item

And Finally... Drugmaker Merck KGaA, which also is the world's largest maker of liquid crystals used in TVs, has offered $2.6 billion to buy Britain's AZ Electronic Materials to broaden that business. Story

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."